How tumor-specific modulation frequencies were discovered

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In the spring of 2001, I visited a longtime friend and collaborator, Alexandre Barbault, to share with him my vision of using low levels radiofrequency electromagnetic fields for the treatment of cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Boris C. Pasche
Charles L. Spurr Professor of Medicine, Chairman, Department of Cancer Biology; Director, Comprehensive Cancer Center of Wake Forest University

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 
Boris C. Pasche
Charles L. Spurr Professor of Medicine, Chairman, Department of Cancer Biology; Director, Comprehensive Cancer Center of Wake Forest University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login